Corteva, Inc. (NYSE: CTVA) ("Corteva" or the "Company") today reported financial results for the third quarter and nine months ended September 30, 2025.
Meets or exceeds all third quarter guidance metrics GAAP Net income of $5.2 million reflects $35 million year-over-year improvement GAAP EPS of $0.11, up $0.86 versus prior-year period Adjusted EPS of ...
Get Q3 2025 Pfizer earnings call insights—guidance raised, major acquisitions, regulatory updates, and R&D highlights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback